Waybiond Biotech Profile
Key Indicators
- Authorised Capital ₹ 10.00 K
as on 03-11-2024
- Paid Up Capital ₹ 10.00 K
as on 03-11-2024
- Company Age 3 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -99.98%
(FY 2023)
- Profit -26775.66%
(FY 2023)
- Ebitda -104117.24%
(FY 2023)
- Net Worth -111547.14%
(FY 2023)
- Total Assets -71.35%
(FY 2023)
About Waybiond Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 K and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Anuj Dhariwal, Sampada Modey, Ambareesh Phadnavis, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239MH2021PTC358237
- Company No.
358237
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Apr 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Waybiond Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prashant Bapat  | Director | 15-Apr-2023 | Current |
| Ambareesh Phadnavis | Director | 01-Apr-2021 | Current |
| Anuj Dhariwal | Director | 18-Sep-2021 | Current |
| Sampada Modey | Director | 01-Apr-2021 | Current |
Financial Performance of Waybiond Biotech.
Waybiond Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 99.98% decrease. The company also saw a substantial fall in profitability, with a 26775.66% decrease in profit. The company's net worth observed a substantial decline by a decrease of 111547.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Waybiond Biotech?
Unlock access to Waybiond Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Greyeast Technologies Private LimitedActive 7 years 6 monthsSampada Modey, Ambareesh Phadnavis and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Waybiond Biotech?
Waybiond Biotech has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Waybiond Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Waybiond Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
